Deals
Takeda Weighing Sale of European Over-the-Counter Assets
- Sale process may start next year as Takeda eyes debt reduction
- Japanese firm could raise about 1 billion euros in disposal
This article is for subscribers only.
Takeda Pharmaceutical Co. is considering a sale of assets from its over-the-counter business in Europe, as the drugmaker pursues ways to cut debt after its $62 billion takeover of Shire Plc, people familiar with the matter said.
The Japanese company is working with advisers at JPMorgan Chase & Co. as it evaluates its options, according to the people, who asked not to be identified because the information is private. A sale process may kick off next year and could value the assets at about 1 billion euros ($1.1 billion), the people said.